Bafna Pharmaceuticals Ltd Stock Price Today (NSE: BAFNAPH)
Fundamental Score
Bafna Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Bafna Pharmaceuticals Ltd share price today is ₹118.15, up +0.00% on NSE/BSE as of 17 February 2026. Bafna Pharmaceuticals Ltd (BAFNAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹364.97 (Cr). The 52-week high for BAFNAPH share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 34.53x, BAFNAPH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.69% and a debt-to-equity ratio of 0.36.
Bafna Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Bafna Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Bafna Pharmaceuticals Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while offering defensive characteristics in economic downturns due to consistent healthcare needs, requires particularly stringent due diligence. The regulatory landscape and evolving patent expirations can significantly impact profitability. This analysis examines the current valuation of Bafna Pharmaceuticals share price, considering fundamental factors relevant to a capital safety-focused value investor. This analysis is part of a detailed 80-parameter fundamental audit verified by Sweta Mishra.
Currently trading at a PE of 34.53, Bafna Pharmaceuticals appears potentially overvalued when considering its Return on Capital Employed (ROCE) of 8.34%. A value investor prioritizes companies generating high returns on invested capital, indicating efficient capital allocation and strong competitive advantages. An 8.34% ROCE, while positive, suggests that Bafna Pharmaceuticals may struggle to build a substantial economic moat, making it more susceptible to competitive pressures.
A critical aspect of value investing is comparing a company to its peers. Considering
Mankind Pharma Ltd, their vastly different market capitalization likely reflects different levels of management expertise, operational efficiency, and overall business execution. While a higher market capitalization does not guarantee superior investment potential, it often correlates with stronger brand recognition, a more established distribution network, and, potentially, a more experienced management team. It is crucial to assess the quality of Bafna Pharmaceuticals' management team relative to its peers.The ROCE directly impacts the company's ability to reinvest earnings and generate future growth. With a lower ROCE compared to an ideal value investment, Bafna Pharmaceuticals may find it more challenging to sustainably grow its earnings at a rate that justifies its current PE ratio. Conservative value investors typically seek companies with a demonstrably high ROCE that acts as a strong barrier to entry for competitors, thus protecting and enhancing future profitability. Further detailed financial statement analysis and understanding of future growth opportunities are essential for making informed decisions about Bafna Pharmaceuticals.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bafna Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BAFNAPH across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Consistent Growth Track Record (27.99% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (18.54% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (40.15% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.69%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.34%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-12.03%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-24.67 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 9.34%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bafna Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Bafna Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About BAFNAPH (Bafna Pharmaceuticals Ltd)
Bafna Pharmaceuticals Ltd (BAFNAPH) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹364.97 (Cr). Bafna Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 7.69% and a ROCE of 8.34%. The debt-to-equity ratio stands at 0.36, reflecting the company's capital structure. Investors tracking BAFNAPH share price can monitor key metrics including P/E ratio, promoter holding of 75.00%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
BAFNAPH Share Price: Frequently Asked Questions
What is the current share price of Bafna Pharmaceuticals Ltd (BAFNAPH)?
As of 17 Feb 2026, 10:08 am IST, Bafna Pharmaceuticals Ltd share price is ₹118.15. The BAFNAPH stock has a market capitalisation of ₹364.97 (Cr) on NSE/BSE.
Is BAFNAPH share price Overvalued or Undervalued?
BAFNAPH share price is currently trading at a P/E ratio of 34.53x, compared to the industry average of 31.77x. Based on this relative valuation, the Bafna Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BAFNAPH share price?
The 52-week high of BAFNAPH share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Bafna Pharmaceuticals Ltd share price?
Key factors influencing BAFNAPH share price include quarterly earnings growth (Sales Growth: -12.03%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Bafna Pharmaceuticals Ltd a good stock for long-term investment?
Bafna Pharmaceuticals Ltd shows a 5-year Profit Growth of 40.15% and an ROE of 7.69%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.36 before investing in BAFNAPH shares.
How does Bafna Pharmaceuticals Ltd compare with its industry peers?
Bafna Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare BAFNAPH share price P/E of 34.53x and ROE of 7.69% against the industry averages to determine competitive standing.
What is the P/E ratio of BAFNAPH and what does it mean?
BAFNAPH share price has a P/E ratio of 34.53x compared to the industry average of 31.77x. Investors pay ₹35 for every ₹1 of annual earnings.
How is BAFNAPH performing according to Bull Run's analysis?
BAFNAPH has a Bull Run fundamental score of 49.8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BAFNAPH belong to?
BAFNAPH operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Bafna Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for BAFNAPH?
BAFNAPH has an ROE of 7.69%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Bafna Pharmaceuticals Ltd generates profits from shareholders capital.
How is BAFNAPH debt-to-equity ratio and what does it indicate?
BAFNAPH has a debt-to-equity ratio of 0.36, which indicates moderate leverage that should be monitored.
What is BAFNAPH dividend yield and is it a good dividend stock?
BAFNAPH offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Bafna Pharmaceuticals Ltd shares.
How has BAFNAPH share price grown over the past 5 years?
BAFNAPH has achieved 5-year growth rates of: Sales Growth 27.99%, Profit Growth 40.15%, and EPS Growth 18.54%.
What is the promoter holding in BAFNAPH and why does it matter?
Promoters hold 75.00% of BAFNAPH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Bafna Pharmaceuticals Ltd.
What is BAFNAPH market capitalisation category?
BAFNAPH has a market capitalisation of ₹365 crores, placing it in the Small-cap category.
How volatile is BAFNAPH stock?
BAFNAPH has a beta of N/A. A beta > 1 suggests the Bafna Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BAFNAPH operating profit margin trend?
BAFNAPH has a 5-year average Operating Profit Margin (OPM) of 10.58%, indicating the company's operational efficiency.
How is BAFNAPH quarterly performance?
Recent quarterly performance shows Bafna Pharmaceuticals Ltd YoY Sales Growth of -12.03% and YoY Profit Growth of 19.08%.
What is the institutional holding pattern in BAFNAPH?
BAFNAPH has FII holding of 9.34% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Bafna Pharmaceuticals Ltd stock.